HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PBYI
Puma Biotechnology, Inc.
PBYI's fundamentals are mixed, but it looks expensive: trading at 18x earnings, above its usual 13x.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PBYI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Strong |
PBYI's cash flow and balance sheet are currently strong, and its revenue and profitability are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PBYI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.4x | $2.49 | -69% |
| Fair | 12x | $5.71 | -29% |
| Current | 18x | $8.08 | — |
| Expensive | 22x | $10.08 | +25% |
Historical ranges are pointers, not guarantees.
PBYI's PE is in its expensive range at 18x.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PBYI Forward outlook
There aren't enough analyst estimates for PBYI to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PBYI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.46 | -39% |
| Q2 2026 | $0.52 | -47% |
| Q1 2026 | $0.48 | -38% |
| Q4 2025 | $0.61 | -1.6% |
| Q3 2025 | $0.75 | +60% |
| Q2 2025 | $0.99 | +450% |
| Q1 2025 | $0.78 | +144% |
| Q4 2024 | $0.62 | +38% |
PBYI has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PBYI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PBYI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.1M | +1.1% |
| Q2 2026 | $56.5M | +7.8% |
| Q1 2026 | $44.8M | -2.6% |
| Q4 2025 | $75.5M | +28% |
| Q3 2025 | $54.5M | -32% |
| Q2 2025 | $52.4M | +11% |
| Q1 2025 | $46M | +5.1% |
| Q4 2024 | $59.1M | -18% |
PBYI's revenue is growing: $55M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -8 points |
| Q2 2026 | 13% | +0.8 points |
| Q1 2026 | -8.5% | -17 points |
| Q4 2025 | 23% | +0.1 points |
| Q3 2025 | 18% | -9.8 points |
| Q2 2025 | 13% | +17 points |
| Q1 2025 | 8.7% | +14 points |
| Q4 2024 | 23% | +2.1 points |
PBYI has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PBYI on cash flow, with more consistent year-over-year improvement.
PBYI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.6M | +51% |
| Q2 2026 | $1.6M | -88% |
| Q1 2026 | $15.4M | +334% |
| Q4 2025 | $14.5M | -7.3% |
| Q3 2025 | $9.7M | -12% |
| Q1 2025 | $3.6M | -68% |
| Q4 2024 | $15.6M | +50% |
| Q3 2024 | $11M | +4.1% |
PBYI generated $46M in free cash flow over the past year, up 7.5% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PBYI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PBYI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +520K shares |
| 1 year | +4.3% | +2.2M shares |
| 3 years | +11% | +5.3M shares |
| 5 years | +30% | +12.3M shares |
| Available history | +36% | +14.1M shares |
PBYI has 53M diluted shares, up 4.3% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PBYI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
PBYI has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PBYI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 35.7 | Neutral |
PBYI's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PBYI PE vs Healthcare Sector
| Metric | PBYI | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 32% below |
| PE % | 70 | 29 | 41 pts above |
PBYI is trading at 18x earnings, a 32% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PBYI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.65 | 16% below |
| 20 week MA | $9.11 | 11% below |
| 50 week MA | $7.65 | 5.6% above |
| 100 week MA | $5.72 | 41% above |
| 200 week MA | $4.69 | 72% above |
PBYI has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PBYI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.66 | $11.4 | +32% |
| 2021 | $11.4 | $3.46 | -70% |
| 2022 | $3.46 | $4.12 | +19% |
| 2023 | $4.12 | $4.33 | +5.1% |
| 2024 | $4.33 | $3.08 | -29% |
| 2025 | $3.08 | $6.16 | +100% |
| 2026 YTD | $6.16 | $8.08 | +31% |
PBYI has the edge over HIMS on returns for 2026, with the stronger performance.